Atrial Fibrillation
Conditions
Keywords
atrial fibrillation,atrial remodeling,dysrhythmias,valsartan
Brief summary
Study purpose The purpose of the study is to show that the addition of valsartan on top of established therapies can reduce the recurrence of atrial fibrillation in patients with a history of recent atrial fibrillation associated with cardiovascular diseases/comorbidities. Primary objective To demonstrate that, in patients with history of recent atrial fibrillation treated with the best recommended therapies, the addition of valsartan 320 mg is superior to placebo in reducing atrial fibrillation recurrence. Study design The GISSI-AF is a prospective, multicenter, randomized, double blind, placebo controlled study. Patients with a history of atrial fibrillation will be centrally randomized in a 1:1 ratio to receive either valsartan or placebo. GISSI-AF will be a pragmatic trial, with broad selection criteria to mimic real clinical practice as much as possible. Since no special examinations or procedures are required for the trial, the economic impact on the National Health Service will be minimized and use of resources likely to be optimized. The enrollment period will last 12 months. The patients will be followed up for 12 months from study entry All prescribed treatments for AF or for the underlying cardiovascular diseases, including ACE-inhibitors, amiodarone and betablockers, will be allowed: * patients should be on a stable treatment for at least one month * the current guideline for hypertension treatment should be applied * patients should not be started on ARBs during the study
Detailed description
The protocol is sponsored by an independent organization and partially supported by Novartis
Interventions
DRUGValsartan
DRUGPlacebo
Sponsors
Gruppo di Ricerca GISSI
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female patients \>=40 years of age 2. Sinus rhythm 3. At least two ECG documented episodes of symptomatic AF in the previous 6 months or After a successful cardioversion for AF performed between 14 days and 48 hours before randomization 4. At least one of the following underlying cardiovascular diseases/comorbidities: * heart failure/documented history of LV dysfunction (defined as an EF \<40%) * history of hypertension \>=6 months with/without LVH * Type II diabetes mellitus * documented history of stroke or peripheral vascular disease * documented history of coronary artery disease * lone atrial fibrillation with documented LA dilation (LA diameter \>=45 mm for men and \>=40 mm for women) 5. Written informed consent to participate in the study prior to any study procedures
Exclusion criteria
1. Need for a continuous treatment with ARBs for any clinical reasons 2. Contraindications or known hypersensitivity to ARBs 3. Persistent standing systolic blood pressure \< 110 mmHg 4. Recent (\<6 weeks) acute myocardial infarction or bypass surgery, or percutaneous coronary intervention 5. Clinically significant valvular etiologies 6. Thyroid dysfunction 7. Indication for pacemaker or ICD implant or for an ablative treatment, recent (\<6 months) PM or ICD implant, previous ablative treatment 8. Planned cardiac surgery, expected to be performed within 3 months 9. Serum creatinine level above 2.5 mg/dL 10. Significant liver disease 11. Pregnant or lactating women or women of childbearing potential who are not protected from pregnancy by an accepted method of contraception 12. Any condition that in the opinion of the investigator would jeopardize the evaluation of efficacy or safety or be associated with poor adherence to the protocol 13. Presence of any non-cardiac disease (e.g. cancer) that is likely to significantly shorten life expectancy 14. Treatment with any investigational agent within 1 month before randomization 15. Currently decompensated heart failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To demonstrate that, in patients with history of recent AF treated with the best recommended therapies, the addition of valsartan (titrated up to 320 mg daily) is superior to placebo in reducing over the whole follow-up: | Time to first AF recurrence |
| First recurrence of AF, | time to first AF recurrence |
| Rate of patients with more than one AF episode, | end of follow-up |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of thromboembolic events | end of fw-up |
| Number of patients who die or with non-fatal thromboembolic events | end of fw-up |
| Number of AF episodes | end of fw-up |
| Number of patients in sinus rhythm who did not have any prior AF recurrence during the study | end of fw-up |
| Duration and characteristics (ventricular rate) of the first recurrence of AF. | end of fw-up |
| Number of patients in sinus rhythm at the time of each study visit | end of fw-up |
| Number of hospitalizations for CV reasons | end of fw-up |
| Number of all-cause hospitalizations | end of fw-up |
Countries
Italy, Switzerland
Outcome results
None listed